At the cutting edge of biotechnology
iX Biopharma focuses on the development and commercialisation of novel wafer formulations to improve the quality of life of those suffering from pain and other health conditions
Add BT as a preferred source
SINCE joining Singapore Exchange (SGX)-listed specialty pharmaceutical company iX Biopharma, Janakan Krishnarajah has been getting involved in many new aspects of the drug making business.
Dr Krishnarajah, a specialist in the fields of clinical pharmacology and internal medicine, had previously held the position of CEO and medical director at Linear Clinical Research - an Australian clinical trials facility.
There, the 42-year-old developed extensive experience in Phases I-IV clinical trials. He acted as principal or co-investigator in more than a hundred Phase I-II clinical trials.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
